AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 222 min read$BLTE

Scholl Hendrik Peter sold $1.5M of BLTE (indirect holdings)

Scholl Hendrik Peter (Chief Medical Officer) sold 10,000 indirectly-held shares of BELITE BIO, INC (BLTE) at an average of $145.24 ($143.90–$147.11, $1.45M total) across 5 trades on 2026-06-18.

Original reporting
SEC EDGAR · Scholl Hendrik Peter
Published Jun 22, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 10:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Neutral
medium confidence
Mentioned
$BLTE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTENeutralLow
01

Why it matters

The newest disclosed fact is the CMO’s open-market sale of 10,000 shares (~$1.45M) executed 2026-06-18 and reported via a filing on 2026-06-22.

02

Market read

Traders may monitor for follow-on insider activity or corroborating fundamental news, but this disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing notes indirect holdings and no stated 10b5-1 plan; without context on total compensation, tax needs, or prior sale patterns, the signal strength is limited.

Relevance 6/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-06-22) for a sale executed 2026-06-18

Background

The article is an SEC Form 4 insider transaction disclosure for Belite Bio, Inc. (BLTE).

Company-level read

Ticker impact

$BLTENeutralMedium confidence
Context

Belite Bio CMO Scholl Hendrik Peter filed a Form 4 selling $1.45M of BLTE shares in an open-market transaction dated 2026-06-18.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source Form 4, but it is an open-market sale with no stated reason, no 10b5-1 plan, and no accompanying operational/regulatory update.

Market effects

Sector

Minimal; this is company-specific insider activity with no disclosed sector-wide regulatory or clinical development.

Regional

None indicated; US-listed filing only.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be routine liquidity/portfolio management rather than a negative view on the business, especially given the multi-trade execution window.

Key entities

  • issuer
    Belite Bio, Inc.

    US-listed company whose insider transaction is disclosed on Form 4.

  • insider
    Scholl Hendrik Peter

    Chief Medical Officer reporting an open-market sale of BLTE shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

SEP 4
$BLTEMedAI 8/10

Belite Bio (BLTE) Is Up 9.0% After FDA Grants Priority Review To Tinlarebant Stargardt NDA

Belite Bio (BLTE) shares rose 9.0% after the FDA granted priority review to its new drug application for tinlarebant, a treatment for Stargardt disease. The company expects a decision by February 12, 2027, and is preparing for commercial launch, targeting 53,000 patients. Phase III data showed a 35.7% reduction in lesion growth versus placebo. The company projects $563.2 million revenue and $318.3 million earnings by 2029, a 24% upside to its current price.

simplywall.st3 min
AUG 12
$BLTEMedAI 8/10

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio (BLTE) said the FDA accepted its tinlarebant NDA for Stargardt disease type I and granted priority review. A decision is expected Feb. 12, 2027. Priority review targets action in six months. The filing is based on Phase III DRAGON results showing a 35.7% reduction in atrophic lesion growth rate vs placebo. BLTE shares rose about 6.2% on Tuesday.

tradingview.com4 min
AUG 12
$BLTEMedAI 8/10

Belite Bio lands priority review for first Stargardt treatment

The FDA accepted and granted priority review to Belite Bio’s (Nasdaq: BLTE) New Drug Application for tinlarebant to treat Stargardt disease type 1. The Prescription Drug User Fee Act target action date is Feb. 12, 2027. The program previously received breakthrough therapy, fast track, and rare pediatric designations, and has orphan drug status in multiple regions.

thepharmaletter.com4 min
JUL 20
$BLTEMedAI 8/10

Why Is Belite Bio Stock Gaining Monday? - Belite Bio (NASDAQ:BLTE)

Belite Bio (NASDAQ:BLTE) reported additional secondary endpoint statistics from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The company said qAF stayed stable or fell about 2% at 25 months with tinlarebant versus about a 20% increase with placebo, and the trial previously met its primary endpoint, reducing retinal lesion growth by 35.7% versus placebo. BLTE shares rose about 3.11% to $154.74.

benzinga.com4 min